drugset / Trial / NCT01965145

Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)

NCT01965145

Phase 3 Terminated 84 enrolled Servier
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to demonstrate the superiority of gevokizumab as compared to placebo on top of current standard of care in reducing the risk of Behçet's disease uveitis exacerbations

Timeline

Start
2012-11
Primary completion
2015-07
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject gevokizumab Monoclonal antibody 60 mg Subcutaneous

Indications